PFE - Pfizer: It Could Be A Bargain
2024-07-02 01:19:04 ET
Summary
- When excluding sales Pfizer generated due to COVID-19 vaccines and medication, the business is reporting solid growth.
- Especially the oncology business will drive growth in the years to come, and the Seagan acquisition might also contribute.
- With its high dividend yield and rather undervalued stock, PFE stock is a "Buy" at this point.
In the last few years, I covered several pharmaceutical companies - including Gilead Sciences, Inc. ( GILD ), Novo Nordisk A/S ( NVO ) or Eli Lilly and Company ( LLY ) - and wrote in one way or another about many different pharmaceutical companies. But one major pharmaceutical company I never wrote about is Pfizer Inc. ( PFE ). The company is one of the oldest and major pharmaceutical companies in the world and among the top 10 pharmaceutical companies (according to market capitalization )....
Pfizer: It Could Be A Bargain